Business
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026PHILADELPHIA, April 30, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today announced the company will deliver an oral presentation at the Ame
About this update from Century Therapeutics, Inc.
[{"type":"image","alt":"Century Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Century Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/1dafc8564c4cf69fd2fbdeedd53053be"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/s6hRg83hRnRWEUSEDPfVRg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNQ--/https://media.zenfs.com/en/globenewswire.com/1dafc8564c4cf69fd2fbdeedd53053be","width":300,"height":89}},"lazy":false},{"type":"text","content":"CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026","length":171,"tagName":"p"},{"type":"text","content":"PHILADELPHIA, April 30, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today announced the company will deliver an oral presentation at the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5–8, 2026 in New Orleans, Louisiana. The presentation will highlight CNTY-813, Century’s iPSC-derived islet cell replacement therapy program engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes.","length":620,"tagName":"p"},{"type":"text","content":"“We are building CNTY-813 with scalability and patient access in mind from day one, and we look forward to sharing new preclinical data at ADA,” said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics. “Advancing a potentially curative islet replacement therapy for a broad T1D population requires not only compelling efficacy and scalable cell production, but also a product that significantly reduces or eliminates the need for chronic immunosuppressive therapy following transplantation. This oral presentation underscores our continued execution across the program as we rapidly advance CNTY-813 through IND-enabling development.”","length":663,"tagName":"p"},{"type":"text","content":"Presentation Details","length":20,"tagName":"p"},{"type":"text","content":"Title: CNTY‑813: Scalable Production of Allo‑Evasion™ 5.0‑Engineered iPSC Beta Islets for Off‑the‑Shelf Cell Therapies Format: Oral Present...